Meeting
2016 ASCO Annual Meeting
The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.
Authors
Alex J Eustace
Medical Oncology, Royal College of Surgeons in Ireland, Dublin, Ireland
Alex J Eustace , Sinead Toomey , Joanna Fay , Ausra Teiserkiene , Malgorzata Milewska , Elaine Kay , Darran O'Connor , Ailis Fagan , Leonie S Young , Norma O'Donovan , Janice Maria Walshe , Arnold D. Hill , M. John Kennedy , Colm Power , Deirdre Duke , Niamh Hambly , William M. Gallagher , John Crown , Bryan Hennessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 587)
DOI
10.1200/JCO.2016.34.15_suppl.587
Abstract #
587
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Effect of TCHL-based therapy on immune cell content in on-treatment, neoadjuvant-treated HER2-positive breast cancer patients.
First Author: Niamh M. Keegan
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant TCH (docetaxel/darboplatin/trastuzumab) versus EC-TH (epirubicin/cyclophosphamide followed by docetaxel/ trastuzumab ) in patients with HER2-positive breast cancer (neoCARH): A randomised, open-label, multicenter, phase II trial.
First Author: Hong-Fei Gao
Poster
2016 ASCO Annual Meeting
Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16).
First Author: Kosuke Kawaguchi